<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oropharyngeal candidiasis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oropharyngeal candidiasis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Oropharyngeal candidiasis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John W Baddley, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Candida</em> species can be associated with infections involving mucosal membranes, including the oropharynx and esophagus. The majority of these infections are related to <em>Candida albicans</em>. </p><p>This topic will review the clinical manifestations, diagnosis, and treatment of oropharyngeal candidiasis in adults. Topic reviews that discuss esophageal and chronic mucocutaneous candidiasis, as well as those that provide an overview of candidal infections, are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a> and  <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/z/d/html/5972.html" rel="external">"Candida infections in children"</a> and  <a class="medical medical_review" href="/z/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a>.)</p><p class="headingAnchor" id="H2183005938"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>The causative agent of oropharyngeal candidiasis is usually <em>C</em>.<em> albicans</em>. Non-<em>albicans</em> species, such as <em>C. glabrata</em>, <em>C. krusei</em>, and <em>C. tropicalis</em> have also been isolated [<a href="#rid1">1-4</a>], but in most patients, these species are usually present along with <em>C. albicans</em>, which is the probable cause of the symptoms. However, in highly immunosuppressed patients, non-<em>albicans</em> species appear to cause disease [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3421975592"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>In adults, oropharyngeal candidiasis (also referred to as thrush) is seen in both immunocompetent and immunocompromised hosts.</p><p class="bulletIndent1"><span class="glyph">●</span>In immunocompetent patients, oropharyngeal candidiasis typically occurs in those who wear dentures [<a href="#rid5">5,6</a>], patients with xerostomia (dry mouth), and those treated with antibiotics or inhaled corticosteroids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In immunocompromised patients, oropharyngeal candidiasis is usually seen in those in those with cellular immune deficiency states, such as patients who have acquired immunodeficiency syndrome (AIDS) or hematologic malignancies, as well as those who have received a transplant. However, it can also occur in patients receiving chemotherapy, corticosteroids, or radiation therapy to the head and neck [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H3205508946"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3836097229"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Many patients with oropharyngeal candidiasis are asymptomatic. However, when symptoms do occur, patients commonly experience a cottony feeling in the mouth, loss of taste, and, in some cases, pain during eating and swallowing. Patients who have denture stomatitis usually experience pain. </p><p>Immunocompromised patients with oropharyngeal candidiasis often have concurrent <em>Candida</em> esophagitis or occasionally laryngeal candidiasis. Laryngeal candidiasis may be suspected in a patient with evidence of oropharyngeal infection who presents with hoarseness. A detailed discussion of <em>Candida</em> esophagitis is presented in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a>.)</p><p><em>Candida</em> species also cause angular cheilitis, a painful fissuring at the corners of the mouth. (See  <a class="medical medical_review" href="/z/d/html/13654.html" rel="external">"Cheilitis", section on 'Angular cheilitis'</a>.)</p><p class="headingAnchor" id="H1160816837"><span class="h2">Physical exam</span><span class="headingEndMark"> — </span>There are two major forms of oropharyngeal candidiasis:</p><p class="bulletIndent1"><span class="glyph">●</span>The pseudomembranous form is the most common and appears as white plaques on the buccal mucosa, palate, tongue, and/or the oropharynx  (<a class="graphic graphic_picture graphicRef75887" href="/z/d/graphic/75887.html" rel="external">picture 1</a>). The disease can be characterized as mild, moderate, or severe based on the extent of the lesions: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild disease: scattered, nonconfluent lesions &gt;2mm in size</p><p class="bulletIndent2"><span class="glyph">•</span>Moderate disease: multiple lesions &gt;2mm in size </p><p class="bulletIndent2"><span class="glyph">•</span>Severe disease: extensive, confluent lesions</p><p></p><p class="bulletIndent1">Patients who have only a white coating on their tongue rarely have candidiasis; this condition is usually caused by hypertrophic papillae. Smokers can have a yellow-brown coating on their tongue from this same cause. (See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Tongue lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The atrophic form, also called denture stomatitis, is seen in older adults who wear upper dentures. It is found under upper dentures and is characterized by erythema without plaques  (<a class="graphic graphic_picture graphicRef79519" href="/z/d/graphic/79519.html" rel="external">picture 2</a>) [<a href="#rid8">8</a>].</p><p></p><p>Angular cheilitis manifests as bilateral, bright red erythematous fissures at the angles of the mouth [<a href="#rid9">9</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13654.html" rel="external">"Cheilitis", section on 'Angular cheilitis'</a>.)</p><p class="headingAnchor" id="H891001315"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of oropharyngeal candidiasis is usually made clinically in patients with risk factors for infection and characteristic findings on exam. (See <a class="local">'Risk factors'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p>However, testing may be warranted in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>If there is a doubt as to whether the exam findings are consistent with thrush; <strong>or </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient does not have the classic risk factors for thrush. The presence of thrush in a person with no obvious risk factors should raise the suspicion of human immunodeficiency virus (HIV) infection, and testing for HIV should be performed. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p></p><p>The diagnosis can be made by simply scraping the lesions with a tongue depressor and performing a Gram stain or potassium hydroxide preparation on the scrapings, which will reveal budding yeasts with or without hyphae. Alternatively, a culture can be obtained by rubbing a swab over a lesion; however, many people have oropharyngeal colonization by <em>Candida</em>; thus, the clinical picture has to be compatible with thrush if the culture is to be helpful.</p><p class="headingAnchor" id="H488830233"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The initial choice of therapy is typically based upon the severity of disease and whether the patient is pregnant  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>). Other considerations include the ease of administration, anticipated adherence, gastric acidity (which may affect absorption of some drugs), drug-drug interactions, and cost. </p><p class="headingAnchor" id="H1075936222"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Patients with clinical evidence of oropharyngeal candidiasis should be treated. Treatment improves symptoms and, in immunocompromised patients, may also reduce the risk of developing esophagitis. Data supporting the efficacy of antifungal treatment are reviewed below. (See <a class="local">'Initial therapy in nonpregnant patients'</a> below and <a class="local">'Patients with recurrent disease'</a> below and <a class="local">'Poor response to initial therapy'</a> below.)</p><p class="headingAnchor" id="H1007865370"><span class="h2">Initial therapy in nonpregnant patients</span></p><p class="headingAnchor" id="H3059116480"><span class="h3">Patients with mild disease</span><span class="headingEndMark"> — </span>For most patients with mild oropharyngeal candidiasis, we suggest topical therapy for 7 to 14 days [<a href="#rid5">5,10,11</a>]. Most patients demonstrate signs of improvement after three days. We prefer topical rather than oral therapy to reduce the risk of drug interactions and systemic toxicity. However, oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> may be preferred for certain patients, such as those who cannot use troches or suspension because of aspiration risk or inability to follow directions and certain immunocompromised patients at risk for disseminated disease due to severe mucosal breakdown (eg, patients with hematologic malignancies). Other experts also prefer initial therapy with fluconazole for all patients with HIV, regardless of CD4 count or disease severity [<a href="#rid12">12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred topical agents </strong>– Our preferred topical options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">Clotrimazole</a> troches (one 10 mg troche dissolved in the mouth five times daily) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">Miconazole</a> mucoadhesive buccal tablets (50 mg once daily applied to the mucosal surface over the canine fossa) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">Nystatin</a> swish and swallow (400,000 to 600,000 units four times daily)</p><p></p><p class="bulletIndent1">We prefer <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> troches or <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> mucoadhesive buccal tablets. Clotrimazole troches and <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> appear to be clinically equally effective for the initial treatment of thrush in patients with AIDS. In a trial of 334 patients with HIV and oral candidiasis who received either oral fluconazole (100 mg daily) or clotrimazole troches (10 mg five times), almost all patients were cured or showed clinical improvement regardless of which treatment they received [<a href="#rid13">13</a>]. Miconazole mucoadhesive buccal tablets were found to be as effective as clotrimazole troches used five times daily in a randomized study of 578 patients with HIV [<a href="#rid14">14</a>]; however, these are more expensive than clotrimazole.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">Nystatin</a> suspension is another option, but it is not always palatable to patients [<a href="#rid15">15</a>], and it contains sucrose, which can cause dental caries when used over prolonged time periods [<a href="#rid16">16</a>]. In addition, nystatin may be less effective than <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> or <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a>. Unlike clotrimazole, nystatin was found to be less effective than <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> in a trial of 167 patients with HIV, in which clinical resolution was seen in 87 and 52 percent of patients who received fluconazole (100 mg once daily) or liquid nystatin (500,000 units four times daily), respectively [<a href="#rid17">17</a>]. In addition, there were fewer relapses at day 28 in those who received fluconazole (18 versus 44 percent), although this difference did not persist over time.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8749" href="/z/d/drug information/8749.html" rel="external">Gentian violet</a> is another topical therapy, but we rarely use this since it is messy and does not appear to be more effective than the other options.</p><p></p><p class="bulletIndent1">Successful therapy with topical agents depends upon adequate contact time between the agent and the oral mucosa [<a href="#rid16">16</a>]. Thus, patients should be able to follow instructions for use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred systemic agents </strong>– For patients with mild disease who require systemic therapy, we typically use <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 mg loading dose, followed by 100 to 200 mg daily for 7 to 14 days)  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>). Data supporting the use of fluconazole are described below. (See <a class="local">'Patients with moderate to severe disease'</a> below.)</p><p></p><p class="headingAnchor" id="H1259878223"><span class="h3">Patients with moderate to severe disease</span><span class="headingEndMark"> — </span>In patients with moderate to severe disease, we suggest systemic therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 mg loading dose, followed by 100 to 200 mg daily for 7 to 14 days) rather than topical therapy  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>). Patients typically improve clinically within a few days after initiating therapy, and in one report, clinical symptoms and signs resolved by the end of treatment in more than 90 percent of patients taking fluconazole [<a href="#rid18">18</a>]. Although the rate of clinical cure appears similar for fluconazole and certain topical therapies, we prefer fluconazole in this group of patients because it was associated with superior mycological cure rates, lower risk of relapse, and longer disease-free interval [<a href="#rid17">17,19</a>]. In addition, fluconazole is more convenient than most topical regimens, which may enhance adherence. </p><p>Other oral azoles (eg, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> oral solution, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> suspension, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>) also appear to be effective for initial therapy [<a href="#rid12">12,15,20-24</a>]; however, we prefer <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> due its ease of administration, low side effect profile, lower risk of drug interactions, and cost. These other agents are typically used for treatment of refractory disease. (See <a class="local">'Poor response to initial therapy'</a> below.)</p><p>Echinocandins and intravenous <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> can also be used as treatment of thrush, but these are rarely indicated. </p><p class="headingAnchor" id="H2398463248"><span class="h2">Poor response to initial therapy</span><span class="headingEndMark"> — </span>For those who have persistent symptoms after several days of therapy, we typically modify the treatment regimen. The approach depends upon the initial choice of therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor response to topical treatment</strong> – If the patient does not respond to topical therapy, the preferred therapy is oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 mg loading dose, then 100 to 200 mg daily) for a total of 7 to 14 days [<a href="#rid1">1,10,11,25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor response to </strong><strong>fluconazole</strong> – For patients who do not respond to initial therapy with 100 to 200 mg of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, the next step is to double the dose of this agent. If this is not successful, a culture should be performed because the symptoms may be due to a species of <em>Candida</em> that is intrinsically resistant to fluconazole or to an isolate of <em>C. albicans</em> that has developed resistance to fluconazole [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">Pending the culture results, we typically switch to <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> since there are data supporting the use of these agents in patients who have thrush refractory to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid26">26-28</a>]. We usually favor itraconazole solution rather than other agents because there are more clinical data for this approach.</p><p></p><p class="bulletIndent1">For patients with refractory disease, we typically treat with one of the following azoles for 14 to 28 days:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Itraconazole</strong><strong> solution</strong> – <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> solution (200 mg once daily) is a suitable option for patients who do not respond to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> therapy [<a href="#rid10">10,12,26</a>]. Itraconazole capsules should <strong>not </strong>be used; although they are more palatable than the solution, they are less effective. In a study of patients with AIDS, itraconazole solution was effective in treating thrush that had become resistant to fluconazole, and it was thought this was likely both a local effect, bathing the mucosa, as well as a systemic effect [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Posaconazole</strong><strong> suspension </strong>– <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> suspension may be an effective alternative for patients with refractory disease [<a href="#rid12">12</a>]. For such patients, posaconazole suspension should be administered (400 mg twice daily for three days and then once daily). In an open-label trial in 149 patients with HIV who were treated with posaconazole suspension for oropharyngeal candidiasis refractory to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, clinical cure or improvement occurred in 74 percent of patients [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent2">Studies demonstrating the efficacy of <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> for thrush were performed with the oral suspension. An extended-release tablet is now available, and most physicians have switched to the tablet formulation for treatment of invasive fungal infections and prophylaxis in immunosuppressed hosts. However, it is unclear how the use of the tablet formulation will impact the efficacy of posaconazole for oropharyngeal candidiasis because it is not known if serum concentrations determine the response of thrush to therapy or if there is a benefit from the local effects of the suspension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Voriconazole</strong> – <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> (200 mg orally twice daily) can be used if needed to treat oropharyngeal infection caused by <em>Candida</em> species that are resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid10">10</a>]. However, data are limited [<a href="#rid28">28</a>], and voriconazole is inherently more toxic than fluconazole. If voriconazole is given for more than two weeks, serum levels should be measured to avoid dose-dependent toxic effects. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a>.) </p><p></p><p class="bulletIndent1">Echinocandins and intravenous amphotericin B can also be used as treatment for refractory thrush  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>) [<a href="#rid10">10</a>], but these are rarely indicated. <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> oral suspension is also available in some countries for treatment of refractory thrush; however, it is not available in the United States and has to be compounded by a pharmacy.</p><p></p><p class="headingAnchor" id="H3859447953"><span class="h2">Patients with recurrent disease</span><span class="headingEndMark"> — </span>Recurrent disease is common if the underlying risk factors are still present (eg, ongoing steroid/chemotherapy use or persistently low CD4 counts). Recurrences are treated in the same manner as the initial episode unless therapy is no longer effective. (See <a class="local">'Poor response to initial therapy'</a> above.) </p><p>For patients with multiple closely spaced recurrences, suppressive therapy with oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (eg, 100 mg daily or 100 mg three times weekly) can be effective at aborting these events [<a href="#rid1">1,3,10,11</a>]. We generally prefer once-daily dosing to reduce the risk of developing resistance, particularly in patients with sustained immunosuppression.</p><p>We do not use topical therapy as suppression because patients tire of using troches and lozenges, and most prefer a single oral tablet.</p><p>As soon as the underlying defect in cell-mediated immunity can be corrected (eg, when CD4 count is &gt;200 cells/microL), suppressive therapy should be stopped in favor of intermittent treatment of each episode, given the effectiveness of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> for treatment of acute disease, the low mortality associated with mucosal candidiasis, the potential for azole resistance and drug interactions, and the associated cost [<a href="#rid12">12</a>]. The risk of developing fluconazole resistance in the setting of azole therapy was demonstrated in a randomized trial of patients with HIV that compared continuous versus episodic fluconazole therapy; in this study, fluconazole resistance was detected in 45 and 36 percent of those who received continuous and episodic therapy, respectively, although there was no statistically significant difference between the arms [<a href="#rid29">29</a>]. </p><p class="headingAnchor" id="H3464358388"><span class="h2">Additional considerations</span></p><p class="headingAnchor" id="H2902787605"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>Oral azoles are teratogenic and should <strong>not</strong> be used during the first trimester for the treatment of mucosal candidiasis. However, <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> troches, <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> buccal tablets, and <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> swish and swallow topical therapies can be used. (See <a class="local">'Patients with mild disease'</a> above and  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Pregnancy'</a>.)</p><p>For patients who have severe thrush in the first trimester, intravenous amphotericin B can be used [<a href="#rid12">12</a>], but this is rarely needed. There are no data regarding the use of echinocandins in pregnancy. </p><p>In the second and third trimester, topical therapy is still preferred; however, for those with refractory disease, the decision to use an azole must be determined on a case-by-case basis. A detailed discussion of the risks of using azoles during pregnancy is presented in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Pregnancy'</a>.) </p><p class="headingAnchor" id="H670380835"><span class="h3">Denture stomatitis</span><span class="headingEndMark"> — </span>Treatment of denture stomatitis requires treatment of the device, in addition to antifungal therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, to avoid relapse  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>) [<a href="#rid18">18</a>]. The dentures must be removed before going to bed, brushed vigorously, and then soaked in a solution of <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> gluconate or a dilute solution of bleach (10 drops in a denture cup filled with water). Other over-the-counter denture care products can be used, but they do not appear to be as effective [<a href="#rid5">5,6,10</a>]. </p><p class="headingAnchor" id="H2398700109"><span class="h3">Angular cheilitis</span><span class="headingEndMark"> — </span>Topical therapies, such as antifungal creams, are suitable for the treatment of angular cheilitis, which can be seen as a manifestation of <em>Candida</em> infection. (See  <a class="medical medical_review" href="/z/d/html/13654.html" rel="external">"Cheilitis", section on 'Angular cheilitis'</a>.)</p><p class="headingAnchor" id="H3031831627"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H25504915"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15787.html" rel="external">"Patient education: Thrush in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> − Oropharyngeal candidiasis, or thrush, is a common local infection usually caused by <em>Candida albicans. </em>(See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> − Disease is typically seen in immunocompetent adults who wear dentures, have received antibiotics, or are being treated with inhaled corticosteroids. In immunocompromised patients, oropharyngeal candidiasis is typically seen in those with cellular immune deficiencies (eg, patients with AIDS, hematologic malignancies, and transplant recipients), those receiving chemotherapy or radiation therapy to the head and neck, and those receiving corticosteroids. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> <strong>and determining severity of infection</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical manifestations</strong> – Oropharyngeal candidiasis most commonly appears as white plaques on the buccal mucosa, palate, tongue, and/or oropharynx  (<a class="graphic graphic_picture graphicRef75887" href="/z/d/graphic/75887.html" rel="external">picture 1</a>). Patients may be asymptomatic or experience a cottony feeling in the mouth, loss of taste, or pain during eating and swallowing. Patients who have denture stomatitis usually experience pain. (See <a class="local">'Signs and symptoms'</a> above and <a class="local">'Physical exam'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>The extent of disease</strong> – The extent of disease influences treatment: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mild disease – Scattered, non-confluent lesions &gt;2 mm in size </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Moderate disease – Multiple lesions &gt;2 mm in size  </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe disease – Extensive, confluent lesions </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> − In patients with characteristic findings and risk factors for infection, the diagnosis is typically based upon clinical findings. Diagnostic testing (identification of yeast forms on Gram stain or potassium hydroxide preparation, or via culture) should be performed if there is doubt as to whether the exam findings are consistent with thrush or if the patient does not have the classic risk factors for thrush. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Goals of treatment</strong> − Treatment improves symptoms and, in immunocompromised patients, may also reduce the risk of developing esophagitis. Treatment options for nonpregnant patients typically include topical agents or azole therapy  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> − Patients with oropharyngeal candidiasis should be treated with antifungal therapy for 7 to 14 days, except in refractory disease when duration can be extended up to 28 days. (See <a class="local">'Initial therapy in nonpregnant patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild disease </strong>− For most patients with mild disease, we suggest topical therapy (<a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> troches or <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> buccal tablets) rather than systemic therapy  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical therapy is effective and has less toxicity and fewer drug interactions. We treat with topical therapy for 7 to 14 days. Most patients begin to improve within three days. Systemic therapy with oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> may be preferred for certain patients with mild disease, such as:  </p><p class="bulletIndent3"><span class="glyph">-</span>Aspiration risk</p><p class="bulletIndent3"><span class="glyph">-</span>Immunocompromised patients at risk for disseminated disease due to mucosal breakdown</p><p class="bulletIndent3"><span class="glyph">-</span>Patients who do not respond to topical treatment after five to seven days </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe disease</strong> − For patients with moderate to severe disease, we suggest systemic treatment with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> rather than other systemic or topical therapies  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Treatment with fluconazole is associated with superior mycological cure rates, lower risk of relapse, and longer disease-free intervals. We treat with fluconazole for 7 to 14 days. (See <a class="local">'Patients with moderate to severe disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory disease</strong> − For patients refractory to oral therapy with initial <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> treatment (100 to 200 mg daily), we increase the fluconazole dose to 200 to 400 mg daily. If there is still no response after several days, we obtain fungal cultures and switch to an alternative agent  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>); we usually favor <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> over other agents because there is more evidence supporting this approach. For patients with refractory disease, systemic treatment is continued until clinical resolution, up to a maximum of 28 days. (See <a class="local">'Poor response to initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recurrent disease </strong>– Recurrent disease is common if the underlying risk factors (ie, immunosuppression) are still present; recurrences are treated in the same manner as the initial episode unless therapy is no longer effective. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with recurrent oropharyngeal candidiasis, we suggest intermittent therapy rather than continuous suppressive therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Intermittent therapy is effective and minimizes the risk of resistance and drug interactions. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have several recurrences within a few months, suppressive therapy may be reasonable; it should be discontinued as soon as the underlying immunodeficiency has resolved. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy considerations </strong>– The preferred treatment of oropharyngeal candidiasis varies during the course of pregnancy: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>First trimester </strong>–<strong> </strong>Oral azoles (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) are teratogenic and should not be administered during the first trimester. Topical therapy (<a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> troches, <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> buccal tablets, or <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> swish and swallow) is preferred  (<a class="graphic graphic_table graphicRef86676" href="/z/d/graphic/86676.html" rel="external">table 1</a>). For severe or refractory disease, intravenous amphotericin B may be used (though is rarely necessary). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Second and third trimester</strong> – Topical therapy is preferred. For severe or refractory disease, the decision to use an azole should be made on a case-by-case basis.</p><p></p><p class="headingAnchor" id="H1856770396"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339.</a></li><li><a class="nounderline abstract_t">Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol 1993; 9:455.</a></li><li><a class="nounderline abstract_t">Redding SW, Dahiya MC, Kirkpatrick WR, et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97:47.</a></li><li><a class="nounderline abstract_t">Redding SW, Kirkpatrick WR, Coco BJ, et al. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 2002; 40:1879.</a></li><li><a class="nounderline abstract_t">Shay K, Truhlar MR, Renner RP. Oropharyngeal candidosis in the older patient. J Am Geriatr Soc 1997; 45:863.</a></li><li><a class="nounderline abstract_t">Iacopino AM, Wathen WF. Oral candidal infection and denture stomatitis: a comprehensive review. J Am Dent Assoc 1992; 123:46.</a></li><li><a class="nounderline abstract_t">Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993; 76:169.</a></li><li><a class="nounderline abstract_t">Budtz-Jørgensen E. Oral mucosal lesions associated with the wearing of removable dentures. J Oral Pathol 1981; 10:65.</a></li><li><a class="nounderline abstract_t">Sharon V, Fazel N. Oral candidiasis and angular cheilitis. Dermatol Ther 2010; 23:230.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.</a></li><li class="breakAll">Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV.  Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/candidiasis-0 (Accessed on March 27, 2023).</li><li><a class="nounderline abstract_t">Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr 1993; 6:1311.</a></li><li><a class="nounderline abstract_t">Vazquez JA, Patton LL, Epstein JB, et al. Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMiLES). HIV Clin Trials 2010; 11:186.</a></li><li><a class="nounderline abstract_t">Klotz SA. Oropharyngeal candidiasis: a new treatment option. Clin Infect Dis 2006; 42:1187.</a></li><li><a class="nounderline abstract_t">Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:170.</a></li><li><a class="nounderline abstract_t">Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24:1204.</a></li><li><a class="nounderline abstract_t">Finlay PM, Richardson MD, Robertson AG. A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Br J Oral Maxillofac Surg 1996; 34:23.</a></li><li><a class="nounderline abstract_t">Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50:658.</a></li><li><a class="nounderline abstract_t">Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42:1179.</a></li><li><a class="nounderline abstract_t">Phillips P, De Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26:1368.</a></li><li><a class="nounderline abstract_t">Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104:33.</a></li><li><a class="nounderline abstract_t">Murray PA, Koletar SL, Mallegol I, et al. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther 1997; 19:471.</a></li><li><a class="nounderline abstract_t">Oude Lashof AM, De Bock R, Herbrecht R, et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer 2004; 40:1314.</a></li><li><a class="nounderline abstract_t">Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990; 34:2267.</a></li><li><a class="nounderline abstract_t">Saag MS, Fessel WJ, Kaufman CA, et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999; 15:1413.</a></li><li><a class="nounderline abstract_t">Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44:607.</a></li><li><a class="nounderline abstract_t">Hegener P, Troke PF, Fätkenheuer G, et al. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12:2227.</a></li><li><a class="nounderline abstract_t">Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41:1473.</a></li></ol></div><div id="topicVersionRevision">Topic 2432 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942935" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8243605" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716255" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11980984" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215341" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Oropharyngeal candidosis in the older patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740572" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Oral candidal infection and denture stomatitis: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8361726" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6792333" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Oral mucosal lesions associated with the wearing of removable dentures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20597942" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oral candidiasis and angular cheilitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502438" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502438" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8254467" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974574" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad®efficacy and safety (SMiLES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575740" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Oropharyngeal candidiasis: a new treatment option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11505264" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195083" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645677" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8536553" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575739" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9636865" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9528717" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9220211" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15177489" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2073120" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555103" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243069" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9833866" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16231260" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
